Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot

Anti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years....

Descripción completa

Detalles Bibliográficos
Autores: Mariscal, Anaís|||0000-0003-1013-4793, Milán, Milena, Baucells, Andrés|||0000-0002-4567-8486, Martínez, Maria Angeles|||0000-0002-2192-8719, Garcia Guillen, Andrea, Trallero Araguás, Ernesto|||0000-0003-3365-4521, Alvarado, Marcelo|||0000-0003-2915-8963, Martinez-Martinez, Laura|||0000-0003-0126-158X, Alserawan, Leticia, Franco Leyva, Teresa|||0000-0002-0250-0274, Sanz-Martínez, María Teresa|||0000-0001-5814-8698, Viñas-Giménez, Laura|||0000-0003-2913-1154, Corominas, Hèctor|||0000-0002-7738-6787, Juárez Rubio, Cándido|||0000-0003-2235-9893, Castellvi, Ivan|||0000-0002-5410-5807, Selva O'Callaghan, Albert|||0000-0003-2823-9761
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:255307
Acceso en línea:https://ddd.uab.cat/record/255307
https://dx.doi.org/urn:doi:10.3389/fimmu.2020.625896
Access Level:acceso abierto
Palabra clave:Dermatomyositis
Cancer
Autoantibody
Diagnosis
Immunoassay
id ES_4d3fee01e59c2f87f8f565903b419cb8
oai_identifier_str oai:ddd.uab.cat:255307
network_acronym_str ES
network_name_str España
repository_id_str
spelling Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House ImmunoblotUsefulness in Clinical PracticeMariscal, Anaís|||0000-0003-1013-4793Milán, MilenaBaucells, Andrés|||0000-0002-4567-8486Martínez, Maria Angeles|||0000-0002-2192-8719Garcia Guillen, AndreaTrallero Araguás, Ernesto|||0000-0003-3365-4521Alvarado, Marcelo|||0000-0003-2915-8963Martinez-Martinez, Laura|||0000-0003-0126-158XAlserawan, LeticiaFranco Leyva, Teresa|||0000-0002-0250-0274Sanz-Martínez, María Teresa|||0000-0001-5814-8698Viñas-Giménez, Laura|||0000-0003-2913-1154Corominas, Hèctor|||0000-0002-7738-6787Juárez Rubio, Cándido|||0000-0003-2235-9893Castellvi, Ivan|||0000-0002-5410-5807Selva O'Callaghan, Albert|||0000-0003-2823-9761DermatomyositisCancerAutoantibodyDiagnosisImmunoassayAnti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1γ. We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebrón Hospital (Barcelona, Spain) tested for anti-TIF-1γ autoantibodies using the Euroline profile and an in-house immunoblot assay. A total of 27 anti-TIF-1γ were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1γ autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1γ autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1γ antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). We recommend using a second validated method to confirm Euroline-detected anti-TIF-1γ antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1γ antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.Universitat Autònoma de Barcelona 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/255307https://dx.doi.org/urn:doi:10.3389/fimmu.2020.625896reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2553072026-06-06T12:50:31Z
dc.title.none.fl_str_mv Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
Usefulness in Clinical Practice
title Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
spellingShingle Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
Mariscal, Anaís|||0000-0003-1013-4793
Dermatomyositis
Cancer
Autoantibody
Diagnosis
Immunoassay
title_short Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
title_full Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
title_fullStr Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
title_full_unstemmed Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
title_sort Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot
dc.creator.none.fl_str_mv Mariscal, Anaís|||0000-0003-1013-4793
Milán, Milena
Baucells, Andrés|||0000-0002-4567-8486
Martínez, Maria Angeles|||0000-0002-2192-8719
Garcia Guillen, Andrea
Trallero Araguás, Ernesto|||0000-0003-3365-4521
Alvarado, Marcelo|||0000-0003-2915-8963
Martinez-Martinez, Laura|||0000-0003-0126-158X
Alserawan, Leticia
Franco Leyva, Teresa|||0000-0002-0250-0274
Sanz-Martínez, María Teresa|||0000-0001-5814-8698
Viñas-Giménez, Laura|||0000-0003-2913-1154
Corominas, Hèctor|||0000-0002-7738-6787
Juárez Rubio, Cándido|||0000-0003-2235-9893
Castellvi, Ivan|||0000-0002-5410-5807
Selva O'Callaghan, Albert|||0000-0003-2823-9761
author Mariscal, Anaís|||0000-0003-1013-4793
author_facet Mariscal, Anaís|||0000-0003-1013-4793
Milán, Milena
Baucells, Andrés|||0000-0002-4567-8486
Martínez, Maria Angeles|||0000-0002-2192-8719
Garcia Guillen, Andrea
Trallero Araguás, Ernesto|||0000-0003-3365-4521
Alvarado, Marcelo|||0000-0003-2915-8963
Martinez-Martinez, Laura|||0000-0003-0126-158X
Alserawan, Leticia
Franco Leyva, Teresa|||0000-0002-0250-0274
Sanz-Martínez, María Teresa|||0000-0001-5814-8698
Viñas-Giménez, Laura|||0000-0003-2913-1154
Corominas, Hèctor|||0000-0002-7738-6787
Juárez Rubio, Cándido|||0000-0003-2235-9893
Castellvi, Ivan|||0000-0002-5410-5807
Selva O'Callaghan, Albert|||0000-0003-2823-9761
author_role author
author2 Milán, Milena
Baucells, Andrés|||0000-0002-4567-8486
Martínez, Maria Angeles|||0000-0002-2192-8719
Garcia Guillen, Andrea
Trallero Araguás, Ernesto|||0000-0003-3365-4521
Alvarado, Marcelo|||0000-0003-2915-8963
Martinez-Martinez, Laura|||0000-0003-0126-158X
Alserawan, Leticia
Franco Leyva, Teresa|||0000-0002-0250-0274
Sanz-Martínez, María Teresa|||0000-0001-5814-8698
Viñas-Giménez, Laura|||0000-0003-2913-1154
Corominas, Hèctor|||0000-0002-7738-6787
Juárez Rubio, Cándido|||0000-0003-2235-9893
Castellvi, Ivan|||0000-0002-5410-5807
Selva O'Callaghan, Albert|||0000-0003-2823-9761
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Dermatomyositis
Cancer
Autoantibody
Diagnosis
Immunoassay
topic Dermatomyositis
Cancer
Autoantibody
Diagnosis
Immunoassay
description Anti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1γ. We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebrón Hospital (Barcelona, Spain) tested for anti-TIF-1γ autoantibodies using the Euroline profile and an in-house immunoblot assay. A total of 27 anti-TIF-1γ were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0.3163. Expected prevalence of anti-TIF-1γ autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1γ autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1γ antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). We recommend using a second validated method to confirm Euroline-detected anti-TIF-1γ antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1γ antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/255307
https://dx.doi.org/urn:doi:10.3389/fimmu.2020.625896
url https://ddd.uab.cat/record/255307
https://dx.doi.org/urn:doi:10.3389/fimmu.2020.625896
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407679583092736
score 15,300719